The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2024 | SIERRA: Phase IIIb study of tremelimumab + durvalumab for 1L treatment of advanced unresectable HCC
Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the ongoing Phase IIIb SIERRA trial (NCT05883644) investigating the STRIDE regimen (durvalumab plus tremeliumab) in patients excluded from the Phase III HIMALAYA (NCT03298451) trial, including those with Eastern Cooperative Oncology Group performance status two, main portal vein thrombosis, and Child-Pugh liver cirrhosis. This trial aims to expand the eligibility criteria for the STRIDE regimen in clinical practice. The results of this trial will be crucial in determining the potential for widespread adoption of the STRIDE regimen. This interview took place at the ESMO Asia Congress 2024, held in Singapore, Republic of Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
